---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001411"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:39:36.471703+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q3 net product revenue $232M (+39% YoY); AMVUTTRA Q3 sales $25M; reiterates FY product revenue guide $870-930M

## Summary
- Q3 2022 GAAP net loss $405.9M ($3.32/sh) vs $204.5M ($1.72/sh) YoY; non-GAAP net loss $193.4M ($1.58/sh) vs $189.8M ($1.59/sh).
- Combined net product revenue $232M: TTR $170M (ONPATTRO $145M, AMVUTTRA $25M), GIVLAARI $46M, OXLUMO $16M.
- Reiterated FY 2022 product revenue guidance $870-$930M; lowered collaboration/royalty guidance to $100-$150M from $175-$225M.
- AMVUTTRA U.S. launch strong: $25M net rev in first full quarter, 475 Start Forms, 46% new patients, 54% switches from ONPATTRO.
- Positive APOLLO-B Phase 3 results for patisiran in ATTR cardiomyopathy; sNDA submission on track for late 2022.

## SEC filing metadata
- accession: 0001157523-22-001411
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752322001411/0001157523-22-001411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752322001411/a52953758.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001411
- JSON: https://secwatch.observer/filing/0001157523-22-001411.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001411.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.